MedTrace Logo

"An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."

NCT07238062 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2026-04-17

No results posted yet for this study

Summary

This expanded access protocol is part of IND 32226 to evaluate efficacy and safety of multiple intravenous administrations of allogeneic HB-adMSCs for the treatment of Multiple System Atrophy for up to 7 adult patients who pass pre-screening and a completed screening. The subjects will receive 12 intravenous infusions of HB-adMSCs and 6 intrathecal injections of HB-adMSCs over the course of 44 weeks (1 infusion each month and 1 injection every other month).

Conditions

Interventions

BIOLOGICAL

HB-adMSCs - Hope Biosciences Adipose Derived Mesenchymal Stem Cells

Intravenous and intrathecal infusion of Hope Biosciences allogeneic adipose-derived stem cells

Sponsors & Collaborators

  • Hope Biosciences Research Foundation

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07238062 on ClinicalTrials.gov